Article

Evaluation of gene expression data generated from expired Affymetrix GeneChip microarrays using MAQC reference RNA samples

Division of Systems Biology, National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), 3900 NCTR Road, Jefferson, AR 72079, USA.
BMC Bioinformatics (Impact Factor: 2.67). 10/2010; 11 Suppl 6(Suppl 6):S10. DOI: 10.1186/1471-2105-11-S6-S10
Source: PubMed

ABSTRACT The Affymetrix GeneChip® system is a commonly used platform for microarray analysis but the technology is inherently expensive. Unfortunately, changes in experimental planning and execution, such as the unavailability of previously anticipated samples or a shift in research focus, may render significant numbers of pre-purchased GeneChip® microarrays unprocessed before their manufacturer's expiration dates. Researchers and microarray core facilities wonder whether expired microarrays are still useful for gene expression analysis. In addition, it was not clear whether the two human reference RNA samples established by the MAQC project in 2005 still maintained their transcriptome integrity over a period of four years. Experiments were conducted to answer these questions.
Microarray data were generated in 2009 in three replicates for each of the two MAQC samples with either expired Affymetrix U133A or unexpired U133Plus2 microarrays. These results were compared with data obtained in 2005 on the U133Plus2 microarray. The percentage of overlap between the lists of differentially expressed genes (DEGs) from U133Plus2 microarray data generated in 2009 and in 2005 was 97.44%. While there was some degree of fold change compression in the expired U133A microarrays, the percentage of overlap between the lists of DEGs from the expired and unexpired microarrays was as high as 96.99%. Moreover, the microarray data generated using the expired U133A microarrays in 2009 were highly concordant with microarray and TaqMan® data generated by the MAQC project in 2005.
Our results demonstrated that microarray data generated using U133A microarrays, which were more than four years past the manufacturer's expiration date, were highly specific and consistent with those from unexpired microarrays in identifying DEGs despite some appreciable fold change compression and decrease in sensitivity. Our data also suggested that the MAQC reference RNA samples, stored at -80°C, were stable over a time frame of at least four years.

Download full-text

Full-text

Available from: Zhining Wen, Dec 19, 2013
1 Follower
 · 
141 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of two serotonergic drugs, CGS 120 66B acting specifically and TFMPP acting preferentially onto 5-HT1B receptors, was compared in preisolated and in pregrouped mice. Two mice put under an inverted beaker attempt to escape. The number of escape attempts of mice preisolated for 7 days was half that of pregrouped mice. In preisolated mice, TFMPP and CGS 120 66B increased the number of escape attempts up to, respectively, 200% and 300% of that of preisolated control mice. In pregrouped mice, CGS 120 66B was nearly inactive and TFMPP exerts a smaller effect. These results suggest that isolation increases the apparent responsiveness to 5-HT1B stimulants.
    Pharmacology Biochemistry and Behavior 11/1991; 40(2):279-81. DOI:10.1016/0091-3057(91)90552-D · 2.82 Impact Factor
  • Source
    BMC Bioinformatics 10/2010; 11 Suppl 6(Suppl 6):S1. DOI:10.1186/1471-2105-11-S6-S1 · 2.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular biomarkers that are based on mRNA transcripts are being developed for the diagnosis and treatment of a number of diseases. DNA microarrays are one of the primary technologies being used to develop classifiers from gene expression data for clinically relevant outcomes. Microarray assays are highly multiplexed measures of comparative gene expression but have a limited dynamic range of measurement and show compression in fold change detection. To increase the clinical utility of microarrays, assay controls are needed that benchmark performance using metrics that are relevant to the analysis of genomic data generated with biological samples. Ratiometric controls were prepared from commercial sources of high quality RNA from human tissues with distinctly different expression profiles and mixed in defined ratios. The samples were processed using six different target labeling protocols and replicate datasets were generated on high density gene expression microarrays. The area under the curve from receiver operating characteristic plots was calculated to measure diagnostic performance. The reliable region of the dynamic range was derived from log(2) ratio deviation plots made for each dataset. Small but statistically significant differences in diagnostic performance were observed between standardized assays available from the array manufacturer and alternative methods for target generation. Assay performance using the reliable range of comparative measurement as a metric was improved by adjusting sample hybridization conditions for one commercial kit. Process improvement in microarray assay performance was demonstrated using samples prepared from commercially available materials and two metrics - diagnostic performance and the reliable range of measurement. These methods have advantages over approaches that use a limited set of external controls or correlations to reference sets, because they provide benchmark values that can be used by clinical laboratories to help optimize protocol conditions and laboratory proficiency with microarray assays.
    BMC Biotechnology 04/2011; 11:38. DOI:10.1186/1472-6750-11-38 · 2.59 Impact Factor
Show more